EXACT Sciences Target of Unusually Large Options Trading (EXAS)
Shares of EXACT Sciences (NASDAQ:EXAS) saw unusually large options trading on Thursday. Traders purchased 5,900 call options on the stock, AmericanBankingNews.com reports. This represents an increase of 134% compared to the typical daily volume of 2,517 call options.
A number of analysts have recently weighed in on EXAS shares. Analysts at JMP Securities raised their price target on shares of EXACT Sciences from $22.00 to $28.00 in a research note on Wednesday. They now have a “market outperform” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of EXACT Sciences from $21.00 to $23.00 in a research note on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity reiterated a “buy” rating on shares of EXACT Sciences in a research note on Tuesday, August 12th. They now have a $20.00 price target on the stock, up previously from $19.00. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $21.00.
Shares of EXACT Sciences (NASDAQ:EXAS) traded down 3.42% on Thursday, hitting $21.43. 2,409,237 shares of the company’s stock traded hands. EXACT Sciences has a one year low of $9.53 and a one year high of $22.25. The stock’s 50-day moving average is $17.22 and its 200-day moving average is $14.72. The company’s market cap is $1.777 billion.
EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, July 22nd. The company reported ($0.24) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.25) by $0.01. During the same quarter last year, the company posted ($0.19) earnings per share. Analysts expect that EXACT Sciences will post $-1.14 EPS for the current fiscal year.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.